Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
  • A61P31/18—Antivirals for RNA viruses for HIV

Definitions

• This invention relates to the long term treatment of HIV infection by intermittently administering a parenteral formulation comprising the NNRTI TMC278 at relatively long time intervals.
• HIV Human Immunodeficiency Virus
• AIDS acquired immunodeficiency syndrome
• NRTIs nucleoside reverse transcriptase inhibitors
• NRTIs non-nucleoside reverse transcriptase inhibitors
• NtRTIs nucleotide reverse transcriptase inhibitors
• PIs HIV-protease inhibitors
• NNRTI NNRTI
• An NNRTI currently in development is the compound 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]-amino]-benzonitrile, also referred to as TMC278.
• TMC278 This compound not only shows pronounced activity against wild type HIV, but also against many of its mutated variants.
• the compound TMC278, its pharmacological activity as well as a number of procedures for its preparation have been described in WO-03/16306.
• Various conventional pharmaceutical dosage forms including tablets, capsules, drops, suppositories, oral solutions and injectable solutions are exemplified therein.
• a high pill burden is undesirable for many reasons, such as the frequency of intake, often combined with the inconvenience of having to swallow large dosage forms, as well as the need to store and transport a large number or volume of pills.
• a high pill burden increases the risk of patients not taking their entire dose, thereby failing to comply with the prescribed dosage regimen. As well as reducing the effectiveness of the treatment, this also leads to the emergence of viral resistance.
• the problems associated with a high pill burden are multiplied where a patient must take a combination of different anti-HIV agents.
• HIV inhibitory therapy that reduces pill burden in that it involves the administration of dosage forms of relatively small size and additionally does not require frequent dosing. It would be attractive to provide anti-HIV therapy involving the administration of dosage forms at long time intervals such as one week or longer, or even one month or longer.
• the present invention relates to the use of a parenteral formulation comprising an anti-virally effective amount of TMC278 or a pharmaceutically acceptable acid-addition salt thereof, and a carrier, for the manufacture of a medicament for the treatment of a subject infected with HIV, wherein the formulation is to be administered intermittently at a time interval that is in the range of one week to one year.
• the present invention relates to the use of a parenteral formulation comprising an anti-virally effective amount of TMC278 or a pharmaceutically acceptable acid-addition salt thereof, and a carrier, for the treatment of a subject infected with HIV, wherein the formulation is to be administered intermittently at a time interval that is in the range of one week to one year.
• a method of treating a subject infected with HIV comprising the administration of a parenteral formulation comprising an anti-virally effective amount of TMC278 or a pharmaceutically acceptable acid-addition salt thereof, and a carrier, wherein the formulation is administered intermittently at a time interval that is in the range of one week to one year.
• the invention concerns a use or a method as specified herein, wherein the parenteral formulation is administered or is to be administered at a time interval that is in the range of one week to one month, or in the range of one month to three months, or in the range of three months to six months, or in the range of six months to twelf months.
• the invention concerns a use or a method as specified herein, wherein the parenteral formulation is administered or is to be administered once every two weeks, or once every month, or once every three months.
• the compound used in the invention is 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile, having the generic name rilpivirine, also known as TMC278 (or previously referred to as R278474).
• TMC278 is in clinical development as a HIV inhibitor belonging to the class of the NNRTIs.
• TMC278 can be used in base form or as a pharmaceutically acceptable salt form, in particular as an acid addition salt form.
• the pharmaceutically acceptable addition salts are meant to comprise the therapeutically active non-toxic salt forms.
• the acid addition salt forms can be obtained by treating the base form with appropriate acids as inorganic acids, for example, hydrohalic acids, e.g.
• hydrochloric, hydrobromic, and the like sulfuric acid; nitric acid; phosphoric acid and the like; or organic acids, for example, acetic, propanoic, hydroxyacetic, 2-hydroxypropanoic, 2-oxopropanoic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, 2-hydroxy-1,2,3-propanetricarboxylic, methanesulfonic, ethanesulfonic, benzenesulfonic, 4-methylbenzenesulfonic, cyclohexanesulfamic, 2-hydroxybenzoic, 4-amino-2-hydroxybenzoic, and the like acids.
• organic acids for example, acetic, propanoic, hydroxyacetic, 2-hydroxypropanoic, 2-oxopropanoic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, 2-hydroxy-1,2,3-propane
• addition salts also comprises the hydrates and the solvent addition forms that can be derived of the compound TMC278. Examples of such forms are e.g. hydrates, alcoholates, and the like.
• TMC278 occurs in stereoisomeric forms, more in particular as E- and Z-isomeric forms. Both isomers may be used in the present invention. Whenever reference is made herein to TMC278, the E- or the Z-form as well as any mixture of both forms are meant to be included.
• a preferred form of TMC278 for use in the invention is the E-isomer, i.e. (E)-4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]-amino]-benzonitrile, which may be referred to as E-TMC278.
• E-TMC278 The Z-isomer of TMC278, i.e.
• Z-TMC278 (Z)-4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]-amino]-benzonitrile, which may be referred to as Z-TMC278), can also be used.
• E-TMC278 the pure E-isomer or any isomeric mixture of the E- and the Z-forms wherein the E-form is predominantly present is meant to be comprised, i.e. an isomeric mixture containing more than 50% or in particular more than 80% of the E-form, or even more than 90% of the E-form.
• E-form substantially free of the Z-form refers to E-Z-mixtures with no or almost no Z-form, e.g. isomeric mixtures containing as much as 90%, in particular 95% or even 98% or 99% of the E-form.
• the pure Z-isomer or any isomeric mixture of the Z- and the E-forms wherein the Z-form is predominantly present is meant to be comprised, i.e. an isomeric mixture containing more than 50% or in particular more than 80% of the Z-form, or even more than 90% of the Z-form.
• the Z-form substantially free of the E-form refers to E-Z-mixtures with no or almost no E-form, e.g. isomeric mixtures containing as much as 90%, in particular 95% or even 98% or 99% of the Z-form.
• TMC278 refers to as well the base form as any pharmaceutically acceptable acid-addition salt thereof, and also to the stereoisomeric forms of TMC278 as well as any pharmaceutically acceptable acid-addition salt of said stereoisomeric forms.
• TMC278 refers to the E-isomer of TMC278 as well as its pharmaceutically acceptable acid-addition salts.
• TMC278 as in the present invention may suffice to treat HIV infection, but in a number of cases it may be recommendable to co-administer other HIV inhibitors.
• the latter preferably include HIV inhibitors of other classes, in particular those selected from NRTIs, PIs and fusion inhibitors.
• the other HIV inhibitor that is co-administered is a PI.
• the other HIV inhibitor that is co-administered is a NRTI.
• HIV inhibitors that may be co-administered may be those used in HAART combinations comprising an NNRTI. For example two further NRTIs or an NRTI and a PI may be co-administered. Such co-administration may be by oral administration or parenterally.
• the treatment of HIV infection may be limited to only the administration of a parenteral formulation of TMC278 in accordance with the methodology of this invention, i.e. as monotherapy without co-administration of further HIV inhibitors.
• This option may be recommended, for example, where the viral load is relatively low, for example where the viral load (represented as the number of copies of viral RNA in a specified volume of serum) is below about 200 copies/ml, in particular below about 100 copies/ml, more in particular below 50 copies/ml, specifically below the detection limit of the virus.
• this type of monotherapy is applied after initial treatment with a combination of HIV drugs, in particular with any of the HAART combinations during a certain period of time until the viral load in blood plasma reaches the afore mentioned low viral level.
• the present invention relates to the use of a parenteral formulation comprising an anti-virally effective amount of TMC278 or a pharmaceutically acceptable acid-addition salt thereof, and a carrier, for treating a subject infected with HIV, or for the manufacture of a medicament for treating a subject infected with HIV, wherein the formulation is to be administered after treatment of said subject with a combination of HIV inhibitors and the formulation is administered intermittently at a time interval that is in the range of one week to one year.
• the present invention provides a method for the long term treatment of a subject infected with HIV, said method comprising
• the intermittent treatment with a parenteral formulation of TMC278 is or is to be started after the treatment with a combination of anti-HIV drugs reducing the viral load to below about 200 copies/ml, in particular below about 100 copies/ml, more in particular below 50 copies/ml, or below the detection limit of the virus.
• the parenteral formulations of TMC278 are administered intermittently at a time interval of at least one week, or in particular at a time interval mentioned herein, meaning that the parenteral formulation is administered without any interjacent additional administrations of TMC278.
• TMC278 is administered at particular points in time separated from one another by a time period of at least one week, or in particular at a time interval mentioned herein, during which no TMC278 is administered.
• the administration schedule is simple, requiring few administrations, and therefore dramatically reduces the problem of “pill burden” faced with standard HIV medication. This in turn will improve the patient's compliance to the prescribed medication.
• the parenteral formulations of TMC278 can be administered at time intervals mentioned above.
• the time interval is in the range of one to two weeks, or two to three weeks, or three to four weeks.
• the time interval is in the range of one to two months, or two to three months, or three to four months.
• the time interval may be at least one week, but may also be several weeks, e.g. 2, 3, 4, 5 or 6 weeks, or at time intervals of one month, or of several months, e.g. 2, 3, 4, 5 or 6 months or even longer, e.g. 7, 8, 9 or 12 months.
• the parenteral formulation is administered at a time interval of one, two or three months.
• TMC278 The time intervals between each administration of a parenteral formulation of TMC278 may vary. For example, the intervals may be shorter where the blood plasma levels of TMC278 are deemed too low, e.g. when these approach the minimum blood plasma level specified hereinafter. The intervals may be longer where the blood plasma levels of TMC278 are deemed too high.
• the parenteral formulations of TMC278 are administered at the same time intervals, for example every week, or every two weeks, every month, or at every time interval mentioned herein. Having time intervals of the same length has the advantage that the administration is e.g. at the same day in the week, or the same day in the month, thereby contributing to compliance of the therapy.
• treatment of HIV infection relates to a situation of the treatment of a subject being infected with HIV.
• subject in particular relates to a human being.
• parenteral formulation is administered in a single administration, for example by one injection after a time interval of at least one week, e.g. by one injection every week or by one injection every month.
• the dose of TMC278 administered which is the amount of TMC278 in the parenteral formulation for use in the invention, is selected such that the blood plasma concentration of TMC278 is kept during a prolonged period of time above a minimum blood plasma level.
• minimum blood plasma level in this context refers to the lowest efficacious blood plasma level, the latter being that blood plasma level of TMC278 that provides effective treatment of HIV, or in alternative wording, that blood plasma level of TMC278 that is effective in suppressing HIV.
• an “effective treatment of HIV”, “effectively suppress viral load”, or similar terms mean that the treatment results in the multiplication of HIV being suppressed to such a level that the viral load is relatively low, for example to a viral load (represented as the number of copies of viral RNA in a specified volume of serum) below about 200 copies/ml, in particular below about 100 copies/ml, more in particular below 50 copies/ml, specifically below the detection limit of the virus.
• An “effective amount” refers to such an amount of TMC278 that, upon administration, reduces the viral load, in particular reduces the viral load below the number of copies mentioned above.
• the term “effective blood plasma levels” refers to those blood plasma levels of TMC278 that result in a reduction of the viral load, in particular below the number of copies mentioned above.
• the blood plasma level of TMC278 is kept at a level above a minimum blood plasma level that is in the range of about 5 to about 500 ng/ml, or about 5 ng/ml to about 200 ng/ml, or about 5 ng/ml to about 100 ng/ml, or about 10 ng/ml to about 50 ng/ml. More in particular, the blood plasma level of TMC278 is kept at a level above a minimum blood plasma level that is in the range of about 5 to about 50 ng/ml, or in the range of about 10 to about 50 ng/ml, or in the range of about 15 to about 50 ng/ml.
• the blood plasma level of TMC278 is kept at a level above a minimum blood plasma level of about 10 ng/ml, or about 15 ng/ml, or about 20 ng/ml, or about 40 ng/ml, or about 100 ng/ml, or about 200 ng/ml, or about 400 ng/ml. In a particular embodiment, the blood plasma level of TMC278 is kept above a level of about 13.5 ng/ml, or about 20.3 ng/ml.
• TMC278 should be kept above these threshold blood plasma levels because at lower levels the drug may no longer be effective thereby increasing the risk of mutations.
• TMC278 administered also depends on the time interval at which it is administered. The dose will be higher where administrations are less frequent.
• the dose to be administered each time should be calculated on a basis of about 0.5 mg/day to about 50 mg/day, or about 1 mg/day to about 20 mg/day, or about 1 mg/day to about 10 mg/day, or about 3 mg/day to about 7 mg/day, e.g. about 5 mg/day.
• Multiplying the above mentioned per day doses by the number of days in a given time interval gives the doses or dose ranges for that time interval.
• the blood plasma levels of TMC278 are more or less stable, i.e. they fluctuate within limited margins.
• the blood plasma levels have been found to approach a steady state mode during a prolonged period of time.
• steady state is meant the condition where the amount of drug present in the blood plasma of a subject stays at more or less the same level over a prolonged period of time.
• the plasma levels of TMC278 generally do not show any drops below the minimum plasma level at which the drug is effective.
• the term “stays at more or less the same level” does not exclude that there can be small fluctuations of the plasma concentrations within an acceptable range, e.g. within about 30% in particular, within about 20%, further in particular within about 10%.
• the concentration (or “C”) of TMC278 in the plasma of a subject is generally expressed as mass per unit volume, typically nanograms per milliliter (ng/ml). For convenience, this concentration may be referred to as “plasma drug concentration” or “plasma concentration” herein.
• the plasma concentrations of TMC278 may reach relatively high levels, without causing significant side effects but should not exceed a maximum plasma level (or C max ), which is the blood plasma level where TMC278 causes significant side effects.
• C max a maximum plasma level
• the C max for TMC278 can be determined from the extrapolation of test data in cellular assays or from the evaluation of clinical testing and preferably should not exceed a value of about 1000 ng/ml.
• the parenteral TMC278 formulations may be administered by intravenous injection or preferably by subcutaneous or intramuscular administration.
• the present invention is based on the use of parenteral formulations of the active ingredient TMC278 and therefore the nature of the carrier will have to be selected such as to suit parenteral administration.
• the carrier will be liquid and may be oily but in most cases will be aqueous. In the latter instance, the carrier comprises sterile water, though other ingredients may be included.
• the carrier may also contain a co-solvent, for example an alcohol such as ethanol, propanol, ethylene glycol, propylene glycol, or a polymer acting as co-solvent such as polyethylene glycol (PEG) or polyethoxylated castor oil (Cremophor®).
• additional ingredients may be added to the parenteral formulations of the active ingredient TMC278 that have a solubility promoting effect such as solubilizers and surfactants, or ingredients being both a surfactant and solubilizer.
• additional ingredients are cyclodextrins or cyclodextrin derivatives.
• cyclodextrins are ⁇ -, ⁇ -, ⁇ -cyclodextrins or ethers and mixed ethers thereof wherein one or more of the hydroxy groups of the anhydroglucose units of the cyclodextrin are substituted with C 1-6 alkyl, particularly methyl, ethyl or isopropyl, e.g. randomly methylated ⁇ -CD; hydroxyC 1-6 alkyl, particularly hydroxyethyl, hydroxypropyl or hydroxybutyl; carboxyC 1-6 alkyl, particularly carboxymethyl or carboxyethyl; C 1-6 alkylcarbonyl, particularly acetyl.
• complexants and/or solubilizers are ⁇ -CD, randomly methylated ⁇ -CD, 2,6-dimethyl- ⁇ -CD, 2-hydroxyethyl- ⁇ -CD, 2-hydroxyethyl- ⁇ -CD, 2-hydroxypropyl- ⁇ -CD and (2-carboxymethoxy)propyl- ⁇ -CD, and in particular 2-hydroxypropyl- ⁇ -CD (2-HP- ⁇ -CD).
• poloxamers which are polyoxyethylene, polyoxypropylene block copolymers that conform generally to the formula HO—[CH 2 CH 2 O] x —[CH(CH 3 )CH 2 O] y —[CH 2 CH 2 O] z —H wherein x, y and z can have various values, available under the tradename Pluronic®, e.g. Pluronic® F108, corresponding to poloxamer 338 in which the average values of x, y and z are respectively 128, 54 and 128.
• Pluronic® e.g. Pluronic® F108
• Still other such ingredients are the ⁇ -tocopheryl polyethylene glycol succinates, in particular Vitamin E TGPS; the polyoxyethylene sorbitan fatty acid esters (also referred to as polysorbates), available under the tradename Tween®, e.g. Tween® 80; the polyethylene glycols (PEGs) such as PEG 400.
• Vitamin E TGPS Vitamin E TGPS
• polyoxyethylene sorbitan fatty acid esters also referred to as polysorbates
• Tween® also referred to as polysorbates
• PEGs polyethylene glycols
• the parenteral formulations of the active ingredient TMC278 may further comprise suspending agents and buffers and/or pH adjusting agents, and optionally preservatives and isotonizing agents. Particular ingredients may function as two or more of these agents simultaneously, e.g. behave like a preservative and a buffer, or behave like a buffer and an isotonizing agent.
• Buffering and pH adjusting agents should be used in an amount sufficient to render the dispersion neutral to very slightly basic (up to pH 8.5), preferably in the pH range of 7 to 7.5.
• Particular buffers are the salts of week acids.
• Buffering and pH adjusting agents that can be added may be selected from tartaric acid, maleic acid, glycine, sodium lactate/lactic acid, ascorbic acid, sodium citrates/citric acid, sodium acetate/acetic acid, sodium bicarbonate/carbonic acid, sodium succinate/succinic acid, sodium benzoate/benzoic acid, sodium phosphates, tris(hydroxymethyl)aminomethane, sodium bicarbonate/sodium carbonate, ammonium hydroxide, benzene sulfonic acid, benzoate sodium/acid, diethanolamine, glucono delta lactone, hydrochloric acid, hydrogen bromide, lysine, methanesulfonic acid, monoethanolamine, sodium hydroxide, trome
• Preservatives comprise antimicrobials and anti-oxidants which can be selected from the group consisting of benzoic acid, benzyl alcohol, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), chlorbutol, a gallate, a hydroxybenzoate, EDTA, phenol, chlorocresol, metacresol, benzethonium chloride, myristyl- ⁇ -piccolinium chloride, phenylmercuric acetate and thimerosal.
• Radical scavengers include BHA, BHT, Vitamin E and ascorbyl palmitate, and mixtures thereof.
• Oxygen scavengers include sodium ascorbate, sodium sulfite, L-cysteine, acetylcysteine, methionine, thioglycerol, acetone sodium bisulfate, isoacorbic acid, hydroxypropyl cyclodextrin.
• Chelating agents include sodium citrate, sodium EDTA and malic acid.
• the suspensions conveniently comprise from 0 to 10% (w/v), in particular 0 to 6% of isotonizing agent.
• Typical nonionic isotonifiers are preferred, in particular glycerin, as electrolytes may affect colloidal stability.
• parenteral formulations with TMC278 may be formulated with or in a suitable controlled release or sustained release or sustained release carrier.
• the active ingredient TMC278 may be encapsulated into small polymeric microspheres that degrade slowly and release the active ingredient at a controlled rate.
• microspheres are those wherein the active ingredient is encapsulated in a biodegradable polymer such as polylactide/polyglycolide polymers or copolymers.
• a biodegradable polymer such as polylactide/polyglycolide polymers or copolymers.
• Another polymer based technology is the ReGelTM technology from MacroMed, which uses triblock copolymers of poly(lactide-co-glycolide) and polyethylene glycol. These are thermosensitive and biodegradable polymers that become a gel upon heating and return to their original state upon cooling. These polymers/hydrogels systems are applied as solutions at administration temperature and become insoluble gels at the injection site.
• An insoluble gel depot is formed immediately upon injection and remains at the site for a period of several weeks. Drug release is controlled through a combination of diffusion from and degradation of the polymer.
• Another type of sustained release injectable dosage forms are based on liposomal systems, which can be used in case of lipophilic drugs or lypophilically modified pro-drugs.
• the liposome particles can be coated, e.g. with polyethylene glycol to evade the immune system.
• Still another type of sustained release injectable dosage forms are the microscopic, spherical particles known as DepoFoamTM from SkyePharma. These particles, essentially lipid in nature, contain a multitude of small aqueous chambers encapsulating the drug to be delivered.
• the carrier is selected such that the dosage form is well-tolerated, with minimal or no side effects.
• the parenteral dosage forms of TMC278 when administered in accordance with the present invention provide effective treatment of HIV infection in that the viral load is reduced while keeping viral replication suppressed.
• the limited number of drug administrations and the lack of undesirable side effects after each administration adds to the patients' compliance with the therapy. Patients' compliance may further be improved when selecting parenteral formulations showing good local tolerance and ease of administration.
• This example shows a study aimed at demonstrating that the administration of a parenteral formulation of TMC278 results in stable blood plasma levels during a prolonged period of time.
• a parenteral formulation of TMC278 results in stable blood plasma levels during a prolonged period of time.
• higher blood plasma levels are obtained, for example a dose of about 10 mg/kg is expected to result in effective blood plasma levels.
• stable blood plasma levels of TMC278 are obtained, effectively suppressing viral multiplication.
• the study was performed in order to study the plasma kinetics and the absolute bioavailability of TMC278 in the beagle dog after single intramuscular administration (IM) of an aqueous 30% dimethylacetamide (DMA)/50% polyethylene glycol 400 (PEG400) solution of TMC278 at 2.5 mg/kg.
• IM single intramuscular administration
• DMA dimethylacetamide
• PEG400 polyethylene glycol 400
• Two male beagle dogs (dog No. 16924 and 16854), approximately 3 years old and weighing between 11 and 12 kg at the start of the experimental phase, were used in the present experiment.
• the dogs were dosed intramuscularly at 0.1 ml/kg body weight by injecting the formulation in the left (dog No. 16924) or right (dog No. 16854) m. biceps femoris.
• TMC278 was formulated in an aqueous 30% (w/v) DMA/50% (w/v) PEG400 solution at 25 mg/ml.
• the ingredients of the solution were: TMC278, DMA 30% (w/v), PEG 400 50% (w/v) and pyrogenic free water.
• the content of TMC278 in the formulation was checked using LC.
• the concentration of TMC278 in the formulation was 25 mg/ml.
• a biopsy was performed (dog No. 16924 only) on the iliac lymph node (at the side of injection), on a muscle from the non-injected hind leg and on a muscle at the side of injection after ultrasonographic examination. All tissue samples were protected from light as much as possible and stored on melting ice. All samples were protected from light and stored at ⁇ 18° C. Finally, an additional blood sample was collected on day 272. This sample was processed and analysed similarly to the other blood samples.
• the concentration of TMC278 in dog plasma was determined by a qualified research LC-MS/MS method after solid phase extraction (SPE). Plasma concentrations of TMC278 were determined after proper sample clean up. The samples (0.1 ml aliquots of plasma) were extracted using a solid phase extraction method (Bond Elut Certify solid phase columns, 130 mg, SPE, Varian). The SPE column was conditioned with 3 ml methanol, 3 ml water and 1 ml acetic acid 1 M.
• the concentration of TMC278 in dog tissue samples was also determined by a qualified research LC-MS/MS method.
• Tissues samples were homogenized with a 10-fold dilution in Milli-Q water by means of an Ultra-Turrax.
• the tissue homogenates 200 ⁇ l aliquot) were extracted by adding of 600 ⁇ l methanol (containing TMC278 and/or R152929 and/or methanol). After vortexing and centrifugation, the supernatant was transferred to an HPLC vial and 20 ⁇ l aliquots were injected.
• the LC and the MSMS conditions were the same as described above.
• the lower limit of quantification was 10.0 ng/g tissue. Samples were protected from light during the bioanalytical analysis.
• AUC 0-Tmax ⁇ [(t i+1 ⁇ t i ) ⁇ (C i +C i+1 )/2], and log trapezoidal for the remainder of the curve:
• AUC Tmax-t ⁇ [(t i+1 ⁇ t i ) ⁇ (C i ⁇ C i+1 )/ln(C i /C i+1 )], C i and C i+1 being the plasma concentrations at times t i and t i+1 , respectively.
• the area under the curve extrapolated to infinity (AUC 0- ⁇ ) and the absolute bioavailability of TMC278 in the present formulation could not be calculated adequately since plasma concentrations remained fairly constant or slightly increased between 72 h and 312 h after dosing.
• Time (h) 16854 16924 Mean 0 ⁇ 1.00 ⁇ 1.00 ⁇ 1.00 0.5 13.5 21.3 17.4 1 17.0 23.8 20.4 2 20.6 20.9 20.8 4 27.2 17.1 22.2 8 39.9 15.1 27.5 24 11.4 7.70 9.55 32 10.7 6.65 8.68 48 9.03 6.03 7.53 72 7.37 3.90 5.64 96 6.40 3.97 5.19 144 3.19 3.65 3.42 192 2.80 3.57 3.19 240 6.16 4.38 5.27 312 4.24 5.97 5.11 C max ng/ml 39.9 23.8 31.9 T max h 8 1 5 t 1/2,1-24h h 8.9 1) 15.1 NC 2) t 1/2,24-72h h 75.2 51.0 63.1 AUC 0-312h ng ⁇ h/ml 2122 1603 1863 1) t 1/2,8-24h 2) NC: Not calculated.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• Organic Chemistry (AREA)
• Virology (AREA)
• Communicable Diseases (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Oncology (AREA)
• Epidemiology (AREA)
• Molecular Biology (AREA)
• Tropical Medicine & Parasitology (AREA)
• AIDS & HIV (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicinal Preparation (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (1)

Applications Claiming Priority (5)

Publications (1)

Family

ID=36446113

Family Applications (4)

Family Applications After (3)

Country Status (27)

Families Citing this family (16)

Citations (23)

Family Cites Families (2)

• 2007
  • 2007-01-19 BR BRPI0707179-5A patent/BRPI0707179A2/pt not_active Application Discontinuation
  • 2007-01-19 NZ NZ569347A patent/NZ569347A/en unknown
  • 2007-01-19 KR KR1020087018888A patent/KR101501475B1/ko active Active
  • 2007-01-19 MY MYPI20082697 patent/MY150717A/en unknown
  • 2007-01-19 PL PL07712053T patent/PL1981506T6/pl unknown
  • 2007-01-19 AU AU2007206901A patent/AU2007206901B2/en active Active
  • 2007-01-19 JP JP2008550764A patent/JP5754005B2/ja active Active
  • 2007-01-19 AR ARP070100247A patent/AR059097A1/es not_active Application Discontinuation
  • 2007-01-19 CN CNA2007800024269A patent/CN101370504A/zh active Pending
  • 2007-01-19 US US17/473,424 patent/USRE50189E1/en active Active
  • 2007-01-19 ME MEP-2013-66A patent/ME01617B/me unknown
  • 2007-01-19 CN CN201410126123.XA patent/CN103877091A/zh active Pending
  • 2007-01-19 EA EA200870183A patent/EA014914B1/ru unknown
  • 2007-01-19 CA CA2636436A patent/CA2636436C/fr active Active
  • 2007-01-19 SI SI200731253T patent/SI1981506T1/sl unknown
  • 2007-01-19 DK DK07712053.3T patent/DK1981506T6/da active
  • 2007-01-19 PT PT77120533T patent/PT1981506E/pt unknown
  • 2007-01-19 ES ES07712053T patent/ES2414982T7/es active Active
  • 2007-01-19 EP EP07712053.3A patent/EP1981506B3/fr active Active
  • 2007-01-19 RS RS20130258A patent/RS52821B2/sr unknown
  • 2007-01-19 WO PCT/EP2007/050516 patent/WO2007082922A2/fr not_active Ceased
  • 2007-01-19 US US12/161,445 patent/US10953009B2/en not_active Ceased
  • 2007-01-19 TW TW096101983A patent/TWI458483B/zh active
  • 2007-01-19 SG SG201101585-6A patent/SG170073A1/en unknown
  • 2007-01-19 AP AP2008004535A patent/AP2936A/xx active
  • 2007-01-19 UA UAA200809750A patent/UA96436C2/ru unknown
  • 2007-01-19 KR KR1020147030400A patent/KR101562943B1/ko active Active
  • 2007-01-19 HR HRP20130544TT patent/HRP20130544T4/hr unknown
• 2008
  • 2008-06-12 IL IL192132A patent/IL192132A/en active IP Right Grant
• 2013
  • 2013-01-28 JP JP2013013118A patent/JP5836983B2/ja active Active
  • 2013-06-27 CY CY20131100521T patent/CY1114089T1/el unknown
• 2021
  • 2021-03-01 US US17/188,850 patent/US20210177843A1/en not_active Abandoned
• 2023
  • 2023-08-22 US US18/236,734 patent/US20240226099A1/en not_active Abandoned

Patent Citations (27)

Non-Patent Citations (54)

Also Published As

Similar Documents

Legal Events